FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Chawla Lakhmir S

2. Date of Event Requiring Statement (MM/DD/YYYY)
7/1/2015 

3. Issuer Name and Ticker or Trading Symbol

LA JOLLA PHARMACEUTICAL CO [LJPC]

(Last)        (First)        (Middle)

C/O LA JOLLA PHARMACEUTICAL COMPANY,, 10182 TELESIS COURT, 6TH FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Chief Medical Officer /

(Street)

SAN DIEGO, CA 92121       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)     (1) 2/6/2025   Common Stock   60000.0   $17.34   D    

Explanation of Responses:
( 1)  Represents an option to purchase a total of 60,000 shares of the Issuer's Common Stock previously issued pursuant to a consultancy arrangement. The option was fully vested with respect to one quarter of the underlying shares on the date of grant, with the remaining shares vesting quarterly thereafter over the next three years.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Chawla Lakhmir S
C/O LA JOLLA PHARMACEUTICAL COMPANY,
10182 TELESIS COURT, 6TH FLOOR
SAN DIEGO, CA 92121

Chief Medical Officer

Signatures
/s/ Chester S. Zygmont, III as attorney-in-fact for Lakhmir S. Chawla 7/8/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more La Jolla Pharmaceutical Charts.
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more La Jolla Pharmaceutical Charts.